NeuroScientific Biopharmaceuticals (NSB) Q4 2026 TU earnings summary

Executive summary

• Achieved 80% clinical response in five special access patients with fistulising Crohn's Disease using StemSmart, with no serious adverse events observed.

• Initiated planning for two Phase 2 clinical trials targeting Crohn's Disease in Australia and the US, leveraging positive SAS patient outcomes.

• Progressed technology transfer of StemSmart manufacturing to Q-Gen Cell Therapeutics, entering the critical validation phase.

• Discontinued independent development of EmtinB for glaucoma, shifting to out-licensing and partnership strategy.

Financial highlights

• Cash and cash equivalents stood at $4.6 million as of 30 June 2026.

• Net cash used in operating activities for the quarter was $1.055 million, primarily for R&D ($815k), staff ($94k), and admin/corporate costs ($250k).

• Related party payments for the quarter totaled $101k, covering director fees, salaries, and superannuation.

Outlook and guidance

• Focus remains on executing Phase 2 clinical trials for StemSmart in Crohn's Disease, with key milestones including FDA pre-IND meeting and TGA audit of Q-Gen.

• Completion of technology transfer and regulatory audit with Q-Gen expected in 2H CY2026.

• Continued engagement with investors and pursuit of strategic partnerships for EmtinB.